These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

437 related articles for article (PubMed ID: 34948055)

  • 1. Drug Discovery for
    Ejalonibu MA; Ogundare SA; Elrashedy AA; Ejalonibu MA; Lawal MM; Mhlongo NN; Kumalo HM
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoteric advancement in TB drugs and an overview on the anti-tubercular role of peptides through computational approaches.
    Khusro A; Aarti C; Barbabosa-Pliego A; Salem AZM
    Microb Pathog; 2018 Jan; 114():80-89. PubMed ID: 29174699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational medicinal chemistry for rational drug design: Identification of novel chemical structures with potential anti-tuberculosis activity.
    Koseki Y; Aoki S
    Curr Top Med Chem; 2014; 14(1):176-88. PubMed ID: 24236720
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Macalino SJY; Billones JB; Organo VG; Carrillo MCO
    Molecules; 2020 Feb; 25(3):. PubMed ID: 32033144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opportunities for overcoming tuberculosis: Emerging targets and their inhibitors.
    Yang L; Hu X; Chai X; Ye Q; Pang J; Li D; Hou T
    Drug Discov Today; 2022 Jan; 27(1):326-336. PubMed ID: 34537334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.
    Pieroni M; Wan B; Cho S; Franzblau SG; Costantino G
    Eur J Med Chem; 2014 Jan; 72():26-34. PubMed ID: 24333612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Machine learning and docking models for Mycobacterium tuberculosis topoisomerase I.
    Ekins S; Godbole AA; Kéri G; Orfi L; Pato J; Bhat RS; Verma R; Bradley EK; Nagaraja V
    Tuberculosis (Edinb); 2017 Mar; 103():52-60. PubMed ID: 28237034
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    Jagadeb M; Rath SN; Sonawane A
    J Biomol Struct Dyn; 2019 Aug; 37(13):3388-3398. PubMed ID: 30132739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Applications of Molecular Simulation in the Discovery of Antituberculosis Drugs: A Review.
    Hu JP; Wu ZX; Xie T; Liu XY; Yan X; Sun X; Liu W; Liang L; He G; Gan Y; Gou XJ; Shi Z; Zou Q; Wan H; Shi HB; Chang S
    Protein Pept Lett; 2019; 26(9):648-663. PubMed ID: 31218945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-tubercular Modelling via QSAR Approach, In Silico Design and Virtual Docking Screening of Designed Hypothetical Inhibitors Against DNA gyrase Protein.
    Adeniji SE
    Curr Comput Aided Drug Des; 2021; 17(6):739-758. PubMed ID: 32586260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design.
    Pieroni M; Wan B; Zuliani V; Franzblau SG; Costantino G; Rivara M
    Eur J Med Chem; 2015 Jul; 100():44-9. PubMed ID: 26071857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coumarin hybrid derivatives as promising leads to treat tuberculosis: Recent developments and critical aspects of structural design to exhibit anti-tubercular activity.
    Reddy DS; Kongot M; Kumar A
    Tuberculosis (Edinb); 2021 Mar; 127():102050. PubMed ID: 33540334
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Machine learning and tubercular drug target recognition.
    Fu LM
    Curr Pharm Des; 2014; 20(27):4307-18. PubMed ID: 24245763
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and Structural Elucidation of Novel Benzothiazole Derivatives as Anti-tubercular Agents: In-silico Screening for Possible Target Identification.
    Venugopala KN; Chandrashekharappa S; Pillay M; Bhandary S; Kandeel M; Mahomoodally FM; Morsy MA; Chopra D; Aldhubiab BE; Attimarad M; Alwassil OI; Harsha S; Mlisana K; Odhav B
    Med Chem; 2019; 15(3):311-326. PubMed ID: 29968540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Outline of the Latest Crystallographic Studies on Inhibitor-Enzyme Complexes for the Design and Development of New Therapeutics against Tuberculosis.
    Mori M; Villa S; Ciceri S; Colombo D; Ferraboschi P; Meneghetti F
    Molecules; 2021 Nov; 26(23):. PubMed ID: 34885662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Computational models for in-vitro anti-tubercular activity of molecules based on high-throughput chemical biology screening datasets.
    Periwal V; Kishtapuram S; ; Scaria V
    BMC Pharmacol; 2012 Mar; 12():1. PubMed ID: 22463123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Perspectives on tuberculosis pathogenesis and discovery of anti- tubercular drugs.
    Ntie-Kang F; Yong JN; Owono Owono LC; Sippl W; Megnassan E
    Curr Med Chem; 2014; 21(30):3466-77. PubMed ID: 25005178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent developments of coumarin-containing derivatives and their anti-tubercular activity.
    Hu YQ; Xu Z; Zhang S; Wu X; Ding JW; Lv ZS; Feng LS
    Eur J Med Chem; 2017 Aug; 136():122-130. PubMed ID: 28494250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.